J Am Pharm Assoc (2003). 2024 Jul-Aug;64(4S):102181. doi: 10.1016/j.japh.2024.102181. Epub 2024 Aug 15.
Medications for opioid use disorder are effective in reducing opioid deaths, but access can be an issue. Relocating an outpatient pharmacist for weekly buprenorphine dispensing in an outpatient clinic may facilitate coverage for buprenorphine and mitigate access and counseling barriers.
This study aimed to evaluate whether staffing an outpatient resident pharmacist to dispense in the buprenorphine clinic had a positive impact on (1) mean cost per prescription charged to charity care and (2) basic elements of patient satisfaction with the on-site pharmacist.
Patient demographics, buprenorphine formulation, insurance type, and uncovered costs were abstracted from dispensing records in the 16 weeks before the pharmacist clinic presence and 16 weeks with the pharmacist present. The difference in insurance types across the 2 periods was tested using a chi-square test, and the mean uncovered prescription costs charged to charity care for the 2 periods was compared using an independent-samples t test. A brief survey was administered while the pharmacist was on-site to evaluate satisfaction, which was analyzed with frequencies of "yes" responses and free-text comments.
A total of 38 patients received buprenorphine during both the pre- and postperiods. Once the pharmacist was on-site, more patients used Medicaid or private insurance, decreasing the mean uncovered cost per prescription from $55.00 (SD 68.7) to $36.97 (SD 60.1) (P = 0.002). Patients reported high levels of satisfaction with most reporting they were more likely to ask questions, pick up their prescriptions, and take their medicine with the pharmacist in the clinic.
The pharmacist successfully transitioned a portion of prescriptions previously covered by charity care to Medicaid or private insurance. This shift led to a decrease in charity care costs by $2950.20 and a reduction in the average uncovered cost per prescription. The pharmacist's presence in the clinic seemed to reduce barriers especially related to inconvenience.
阿片类药物使用障碍的药物治疗在降低阿片类药物死亡方面是有效的,但药物的可及性可能是一个问题。将门诊药剂师每周到门诊分发丁丙诺啡的工作地点转移,可能会更有利于丁丙诺啡的覆盖,并减轻获得药物和咨询方面的障碍。
本研究旨在评估为丁丙诺啡诊所配备一名门诊驻店药剂师是否会对以下方面产生积极影响:(1)慈善医疗服务中每张处方的平均收费;(2)患者对现场药剂师的满意度的基本要素。
从配药记录中提取药剂师到诊前 16 周和到诊后 16 周的患者人口统计学信息、丁丙诺啡配方、保险类型和未覆盖的费用。使用卡方检验比较这两个时期的保险类型差异,使用独立样本 t 检验比较两个时期慈善医疗服务中每张处方的平均未覆盖费用。在药剂师在场时进行了简短的调查,以评估满意度,对“是”的回答频率和自由文本评论进行了分析。
共有 38 名患者在两个时期都接受了丁丙诺啡治疗。药剂师到诊后,更多的患者使用了医疗补助或私人保险,使每张处方的未覆盖费用从 55.00 美元(SD 68.7)降至 36.97 美元(SD 60.1)(P=0.002)。患者对大部分满意度报告非常高,报告称他们更有可能向药剂师提问、领取处方和服药。
药剂师成功地将以前由慈善医疗服务覆盖的部分处方转为医疗补助或私人保险。这一转变使慈善医疗服务的成本减少了 2950.20 美元,每张处方的平均未覆盖费用也减少了。药剂师在诊所的存在似乎减少了障碍,特别是与不便相关的障碍。